Literature DB >> 26572537

Clinical Trials in Spinal and Bulbar Muscular Atrophy-Past, Present, and Future.

Patrick Weydt1, Anna Sagnelli2, Angela Rosenbohm3, Pietro Fratta4, Pierre-François Pradat5,6, Albert C Ludolph3, Davide Pareyson7.   

Abstract

Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy's disease, is a rare adult-onset lower motor neuron disorder with a classic X-linked inheritance pattern. It is caused by the abnormal expansion of the CAG-repeat tract in the androgen receptor gene. Despite important progress in the understanding of the molecular pathogenesis and the availability of a broad set of model organisms, successful translation of these insights into clinical interventions remains elusive. Here we review the available information on clinical trials in SBMA and discuss the challenges and pitfalls that impede therapy development. Two important factors are the variability of the complex neuro-endocrinological phenotype and the comparatively low incidence of the disease that renders recruitment for clinical trials demanding. We propose that these challenges can be and need to be overcome by fostering closer collaborations between clinical research centers, the patient communities and the industry and non-industry sponsors of clinical trials.

Entities:  

Keywords:  Clinical trials; Kennedy disease; Spinal and bulbar muscular atrophy; Therapy development

Mesh:

Substances:

Year:  2015        PMID: 26572537     DOI: 10.1007/s12031-015-0682-7

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  26 in total

Review 1.  Developing treatment for spinal and bulbar muscular atrophy.

Authors:  Kenneth H Fischbeck
Journal:  Prog Neurobiol       Date:  2012-06-02       Impact factor: 11.685

2.  IGF-1: elixir for motor neuron diseases.

Authors:  Theodora Papanikolaou; Lisa M Ellerby
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

3.  210th ENMC International Workshop: Research and clinical management of patients with spinal and bulbar muscular atrophy, 27-29 March, 2015, Naarden, The Netherlands.

Authors:  Maria Pennuto; Linda Greensmith; Pierre-François Pradat; Gianni Sorarù
Journal:  Neuromuscul Disord       Date:  2015-06-19       Impact factor: 4.296

4.  Pilot trial of clenbuterol in spinal and bulbar muscular atrophy.

Authors:  Giorgia Querin; Carla D'Ascenzo; Enrico Peterle; Mario Ermani; Luca Bello; Paola Melacini; Lucia Morandi; Letizia Mazzini; Vincenzo Silani; Monika Raimondi; Jessica Mandrioli; Silvia Romito; Corrado Angelini; Elena Pegoraro; Gianni Sorarù
Journal:  Neurology       Date:  2013-05-03       Impact factor: 9.910

5.  Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy.

Authors:  M Li; Y Nakagomi; Y Kobayashi; D E Merry; F Tanaka; M Doyu; T Mitsuma; Y Hashizume; K H Fischbeck; G Sobue
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

6.  Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.

Authors:  Lindsay E Fernández-Rhodes; Angela D Kokkinis; Michelle J White; Charlotte A Watts; Sungyoung Auh; Neal O Jeffries; Joseph A Shrader; Tanya J Lehky; Li Li; Jennifer E Ryder; Ellen W Levy; Beth I Solomon; Michael O Harris-Love; Alison La Pean; Alice B Schindler; Cheunju Chen; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Lancet Neurol       Date:  2011-01-06       Impact factor: 44.182

7.  Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker.

Authors:  Haruhiko Banno; Hiroaki Adachi; Masahisa Katsuno; Keisuke Suzuki; Naoki Atsuta; Hirohisa Watanabe; Fumiaki Tanaka; Manabu Doyu; Gen Sobue
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

8.  Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Yu Takeuchi; Motoshi Kawashima; Ichiro Yabe; Hidenao Sasaki; Masashi Aoki; Mitsuya Morita; Imaharu Nakano; Kazuaki Kanai; Shoichi Ito; Kinya Ishikawa; Hidehiro Mizusawa; Tomotaka Yamamoto; Shoji Tsuji; Kazuko Hasegawa; Takayoshi Shimohata; Masatoyo Nishizawa; Hiroaki Miyajima; Fumio Kanda; Yasuhiro Watanabe; Kenji Nakashima; Akira Tsujino; Taro Yamashita; Makoto Uchino; Yasushi Fujimoto; Fumiaki Tanaka; Gen Sobue
Journal:  Lancet Neurol       Date:  2010-08-04       Impact factor: 44.182

9.  Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease).

Authors:  N Preisler; G Andersen; F Thøgersen; C Crone; T D Jeppesen; F Wibrand; J Vissing
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

Review 10.  New routes to therapy for spinal and bulbar muscular atrophy.

Authors:  Anna Rocchi; Maria Pennuto
Journal:  J Mol Neurosci       Date:  2013-02-19       Impact factor: 3.444

View more
  11 in total

1.  Introduction to the Special Issue on Spinal and Bulbar Muscular Atrophy.

Authors:  Maria Pennuto; Illana Gozes
Journal:  J Mol Neurosci       Date:  2016-02-13       Impact factor: 3.444

2.  The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy.

Authors:  Angela Rosenbohm; Susanne Hirsch; Alexander E Volk; Torsten Grehl; Julian Grosskreutz; Frank Hanisch; Andreas Herrmann; Katja Kollewe; Wolfram Kress; Thomas Meyer; Susanne Petri; Johannes Prudlo; Carsten Wessig; Hans-Peter Müller; Jens Dreyhaupt; Jochen Weishaupt; Christian Kubisch; Jan Kassubek; Patrick Weydt; Albert C Ludolph
Journal:  J Neurol       Date:  2018-02-20       Impact factor: 4.849

3.  Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy.

Authors:  Davide Pareyson; Pietro Fratta; Pierre-François Pradat; Gianni Sorarù; Josef Finsterer; John Vissing; Manu E Jokela; Bjarne Udd; Albert C Ludolph; Anna Sagnelli; Patrick Weydt
Journal:  J Mol Neurosci       Date:  2016-01-07       Impact factor: 3.444

Review 4.  Kennedy's disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease.

Authors:  Marianthi Breza; Georgios Koutsis
Journal:  J Neurol       Date:  2018-07-13       Impact factor: 4.849

5.  Validation of the Italian version of the SBMA Functional Rating Scale as outcome measure.

Authors:  Giorgia Querin; Elisa DaRe; Ilaria Martinelli; Luca Bello; Cinzia Bertolin; Davide Pareyson; Caterina Mariotti; Elena Pegoraro; Gianni Sorarù
Journal:  Neurol Sci       Date:  2016-07-21       Impact factor: 3.307

6.  Previously Undiagnosed Spinal and Bulbar Muscular Atrophy as a Cause of Airway Obstruction after Robot-Assisted Laparoscopic Prostatectomy.

Authors:  Miyuki Niki; Taihei Tachikawa; Yuka Sano; Hiroki Miyawaki; Aisa Matoi; Yukari Okano; Nobutaka Kariya; Tsuneo Tatara; Munetaka Hirose
Journal:  Case Rep Anesthesiol       Date:  2017-07-17

7.  Identification of neuron selective androgen receptor inhibitors.

Authors:  Maya Otto-Duessel; Ben Yi Tew; Steven Vonderfecht; Roger Moore; Jeremy O Jones
Journal:  World J Biol Chem       Date:  2017-05-26

8.  Kennedy disease with difficulty in differential diagnosis: A case report.

Authors:  Yating Chen; Peng Luo; Zhongli Li; Hengping Hu; Duobin Wu; Tingting Xu; Xingzuo Wang; Haiting Xie
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

9.  The French national protocol for Kennedy's disease (SBMA): consensus diagnostic and management recommendations.

Authors:  Pierre-François Pradat; Emilien Bernard; Philippe Corcia; Philippe Couratier; Christel Jublanc; Giorgia Querin; Capucine Morélot Panzini; François Salachas; Christophe Vial; Karim Wahbi; Peter Bede; Claude Desnuelle
Journal:  Orphanet J Rare Dis       Date:  2020-04-10       Impact factor: 4.123

Review 10.  Biomarkers of Spinal and Bulbar Muscle Atrophy (SBMA): A Comprehensive Review.

Authors:  Giorgia Querin; Peter Bede; Veronique Marchand-Pauvert; Pierre-Francois Pradat
Journal:  Front Neurol       Date:  2018-10-10       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.